Related Experiment Video

Updated: Jul 15, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

Effect of Statins on the Inflammatory Markers in Patients with Coronary Artery Disease

Sujatha Mahadevarao Premnath1, Sunil Kumar Nanda1, Lopamudra Ray2

  • 1Department of Biochemistry, Pondicherry Institute of Medical Science, Pondicherry, India.

Journal of Laboratory Physicians
|October 2, 2023
PubMed

Insights

Statin therapy in coronary artery disease (CAD) patients significantly reduces pentraxin 3 (PTX 3) levels, indicating lower inflammation. This study explored PTX 3 and hs-CRP in CAD patients with and without statins.

Area of Science:

  • Cardiovascular Medicine and Atherosclerosis Research
  • Inflammatory Markers in Cardiovascular Disease
  • Pharmacological Effects of Statins

Background:

  • Atherosclerosis, a cornerstone of coronary artery disease (CAD), is driven by inflammatory markers.
  • Hyperlipidemia is a significant risk factor for CAD, commonly managed with statins.
  • Statins possess pleiotropic effects, including the reduction of inflammation.

Purpose of the Study:

  • To estimate serum pentraxin 3 (PTX 3) and high-sensitivity C-reactive protein (hs-CRP) levels in CAD patients.
  • To compare inflammatory marker levels between CAD patients on statin therapy versus those not on lipid-lowering drugs.
  • To correlate PTX 3 and hs-CRP levels with lipid profiles (LDL-c, HDL-c) in CAD patients without statin therapy.

Main Methods:

  • Cross-sectional study involving 62 coronary angiogram-diagnosed CAD patients.
  • Division into two groups: Group I (on statin therapy) and Group II (no prior lipid-lowering drugs).
  • Measurement of serum PTX3, hs-CRP, and lipid profiles; statistical analysis using Student's t-test and Pearson's correlation.

Main Results:

  • Both PTX 3 and hs-CRP levels were elevated above reference ranges in all CAD patients.
  • Significantly lower PTX 3 levels were observed in Group I (statin therapy) compared to Group II (p=0.032).
  • A significant positive correlation was found between PTX 3 and LDL-c in Group II (p=0.003).

Conclusions:

  • CAD patients receiving statin therapy exhibit reduced vessel wall inflammation compared to those not on statins.
  • Statin use is associated with lower levels of the inflammatory marker PTX 3 in CAD patients.
  • PTX 3 levels correlate positively with LDL-c in CAD patients not on lipid-lowering therapy.

Keywords:
C-reactive proteincoronary artery diseasepentraxin 3statins

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.3K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.3K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
691
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9
Inflammation01:38

Inflammation

Overview
53.8K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
23
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
110